Trial Profile
Intravitreal Ranibizumab to Treat Retinopathy of Prematurity Stage 3 Plus Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Adverse reactions
- 01 Jul 2014 New trial record